The Ginkgo biloba extract EGb 761 modulates proteasome activity and polyglutamine protein aggregation

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Stark, Marcel ^a   Behl, Christian ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BAFILOMYCIN A1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GINKGO BILOBA EXTRACT; POLYGLUTAMINE; PROTEASOME;

ARTICLE; AUTOPHAGY; CATALYSIS; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUNTINGTON CHOREA; IMMUNOBLOTTING; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE EXPRESSION;

EID: 84903649702     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/940186     Document Type: Article

References (60)

1. van Beek T. A., Chemical analysis of Ginkgo biloba leaves and extracts. Journal of Chromatography A 2002 967 1 21 55 2-s2.0-0037118913 10.1016/S0021-9673(02)00172-3 (Pubitemid 34786583)
2. Mahadevan S., Park Y., Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. Journal of Food Science 2008 73 1 R14 R19 2-s2.0-38349102172 10.1111/j.1750-3841.2007.00597.x
3. Chan P.-C., Xia Q., Fu P. P., Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. Journal of Environmental Science and Health C: Environmental Carcinogenesis & Ecotoxicology Reviews 2007 25 211 244 10.1080/10590500701569414 (Pubitemid 47347114)
4. Janßen I. M., Sturtz S., Skipka G., Zentner A., Garrido M. V., Busse R., Ginkgo biloba in Alzheimer's disease: a systematic review. Wiener Medizinische Wochenschrift 2010 160 21-22 539 546 2-s2.0-79953304329 10.1007/s10354-010-0844-8
5. Horáková L., Licht A., Sandig G., Jakstadt M., Duracková Z., Grune T., Standardized extracts of flavonoids increase the viability of PC12 cells treated with hydrogen peroxide: effects on oxidative injury. Archives of Toxicology 2003 77 1 22 29 2-s2.0-0037219886 10.1007/s00204-002-0409-8 (Pubitemid 36056979)
6. Maitra I., Marcocci L., Droy-Lefaix M. T., Packer L., Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. Biochemical Pharmacology 1995 49 11 1649 1655 2-s2.0-0029015787 10.1016/0006-2952(95)00089-I
7. Brunetti L., Orlando G., Menghini L., Ferrante C., Chiavaroli A., Vacca M., Ginkgo biloba leaf extract reverses amyloid β -peptide-induced isoprostane production in rat brain in vitro. Planta Medica 2006 72 14 1296 1299 2-s2.0-33845270999 10.1055/s-2006-951688 (Pubitemid 44862030)
8. Smith J. V., Burdick A. J., Golik P., Khan I., Wallace D., Luo Y., Anti-apoptotic properties of Ginkgo biloba extract EGb 761 in differentiated PC12 cells. Cellular and Molecular Biology (Noisy-le-grand) 2002 48 6 699 707 2-s2.0-0036730030
9. Zhuang H., Pin S., Christen Y., Doré S., Induction of heme oxygenase 1 by Ginkgo biloba in neuronal cultures and potential implications in ischemia. Cellular and Molecular Biology (Noisy-le-grand) 2002 48 6 647 653 2-s2.0-2242456603
10. Liu X.-P., Goldring C. E. P., Copple I. M., Wang H.-Y., Wei W., Kitteringham N. R., Park B. K., Extract of Ginkgo biloba induces phase 2 genes through Keap1-Nrf2-ARE signaling pathway. Life Sciences 2007 80 17 1586 1591 2-s2.0-33947178903 10.1016/j.lfs.2007.01.034 (Pubitemid 46412359)
11. Ross C. A., Poirier M. A., Protein aggregation and neurodegenerative disease. Nature Medicine 2004 10 S10 S17 10.1038/nm1066 (Pubitemid 38901862)
12. Kremer B., Goldberg P., Andrew S. E., Theilmann J., Telenius H., Zeisler J., Squitieri F., Lin B., Bassett A., Almqvist E., A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. The New England journal of medicine 1994 330 1401 1406 10.1056/NEJM199405193302001 (Pubitemid 24139231)
13. Krobitsch S., Lindquist S., Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proceedings of the National Academy of Sciences of the United States of America 2000 97 4 1589 1594 2-s2.0-0034652127 10.1073/pnas.97.4.1589 (Pubitemid 30118486)
14. Chai Y., Koppenhafer S. L., Shoesmith S. J., Perez M. K., Paulson H. L., Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Human Molecular Genetics 1999 8 4 673 682 2-s2.0-0033030565 (Pubitemid 29139983)
15. Poirier M. A., Li H., Macosko J., Cai S., Amzel M., Ross C. A., Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. The Journal of Biological Chemistry 2002 277 43 41032 41037 2-s2.0-0037174879 10.1074/jbc.M205809200 (Pubitemid 35215693)
16. Bennett E. J., Bence N. F., Jayakumar R., Kopito R. R., Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Molecular Cell 2005 17 3 351 365 2-s2.0-13244258435 10.1016/j.molcel.2004.12.021 (Pubitemid 40193307)
17. Finkbeiner S., Mitra S., The ubiquitin-proteasome pathway in Huntington's disease. TheScientificWorldJOURNAL 2008 8 421 433 2-s2.0-43449129732 10.1100/tsw.2008.60 (Pubitemid 351669770)
18. Takahashi T., Katada S., Onodera O., Polyglutamine diseases: where does toxicity come from? What is toxicity? Where are we going? Journal of Molecular Cell Biology 2010 2 4 180 191 2-s2.0-78049430399 10.1093/jmcb/mjq005
19. Gamerdinger M., Hajieva P., Kaya A. M., Wolfrum U., Hartl F. U., Behl C., Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3. The EMBO Journal 2009 28 7 889 901 2-s2.0-65449117176 10.1038/emboj.2009.29
20. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G. P., Davies S. W., Lehrach H., Wanker E. E., Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997 90 3 549 558 2-s2.0-18544400323 10.1016/S0092-8674(00)80514-0 (Pubitemid 27347244)
21. Giguere C. J., Schnellmann R. G., Limitations of SLLVY-AMC in calpain and proteasome measurements. Biochemical and Biophysical Research Communications 2008 371 3 578 581 2-s2.0-43549117248 10.1016/j.bbrc.2008.04.133
22. Andreatta C., Nahreini P., Hovland A. R., Kumar B., Edwards-Prasad J., Prasad K. N., Use of short-lived green fluorescent protein for the detection of proteasome inhibition. BioTechniques 2001 30 3 656 660 2-s2.0-0035096666 (Pubitemid 32202871)
23. Kapeta S., Chondrogianni N., Gonos E. S., Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts. The Journal of Biological Chemistry 2010 285 11 8171 8184 2-s2.0-77950907407 10.1074/jbc.M109.031575
24. Pfaffl M. W., Horgan G. W., Dempfle L., Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic acids research 2002 30 9, article e36 2-s2.0-0036581160
25. Luo Y., Smith J. V., Studies on molecular mechanisms of Ginkgo biloba extract. Applied Microbiology and Biotechnology 2004 64 4 465 472 2-s2.0-2542467819 10.1007/s00253-003-1527-9 (Pubitemid 38686154)
26. Bidon C., Lachuer J., Molgó J., Wierinckx A., de la Porte S., Pignol B., Christen Y., Meloni R., Koenig H., Biguet N. F., Mallet J., The extract of Ginkgo biloba EGb 761 reactivates a juvenile profile in the skeletal muscle of sarcopenic rats by transcriptional reprogramming. PLoS ONE 2009 4 11 2-s2.0-71049168859 10.1371/journal.pone.0007998 e7998
27. Luo Y., Smith J. V., Paramasivam V., Burdick A., Curry K. J., Buford J. P., Khan I., Netzer W. J., Xu H., Butko P., Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proceedings of the National Academy of Sciences of the United States of America 2002 99 19 12197 12202 2-s2.0-0037126035 10.1073/pnas.182425199
28. Liggett A., Crawford L. J., Walker B., Morris T. C. M., Irvine A. E., Methods for measuring proteasome activity: current limitations and future developments. Leukemia Research 2010 34 11 1403 1409 2-s2.0-77957019884 10.1016/j.leukres.2010.07.003
29. Kwak M.-K., Wakabayashi N., Greenlaw J. L., Yamamoto M., Kensler T. W., Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Molecular and Cellular Biology 2003 23 23 8786 8794 2-s2.0-0242721624 10.1128/MCB.23.23.8786-8794.2003 (Pubitemid 37433379)
30. Arlt A., Bauer I., Schafmayer C., Tepel J., Müerköster S. S., Brosch M., Röder C., Kalthoff H., Hampe J., Moyer M. P., Fölsch U. R., Schäfer H., Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene 2009 28 45 3983 3996 2-s2.0-70449674487 10.1038/onc.2009.264
31. Park Y., Hong S., Kim S.-J., Kang S., Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product. Molecules and Cells 2005 19 1 23 30 2-s2.0-22844451581
32. Cummings C. J., Reinstein E., Sun Y., Antalffy B., Jiang Y.-H., Ciechanover A., Orr H. T., Beaudet A. L., Zoghbi H. Y., Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 1999 24 4 879 892 2-s2.0-0033391428 10. 1016/S0896-6273(00)81035-1 (Pubitemid 30017667)
33. Krobitsch S., Kazantsev A. G., Huntington's disease: from molecular basis to therapeutic advances. The International Journal of Biochemistry & Cell Biology 2011 43 20 24 10.1016/j.biocel.2010.10.014
34. Bailey C. K., Andriola I. F. M., Kampinga H. H., Merry D. E., Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Human Molecular Genetics 2002 11 5 515 523 2-s2.0-0036501074 10.1093/hmg/11.5.515 (Pubitemid 34257488)
35. Saunders H. M., Gilis D., Rooman M., Dehouck Y., Robertson A. L., Bottomley S. P., Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein. Protein Science 2011 20 10 1675 1681 2-s2.0-80053156781 10.1002/pro.698
36. Michalik A., van Broeckhoven C., Proteasome degrades soluble expanded polyglutamine completely and efficiently. Neurobiology of Disease 2004 16 1 202 211 2-s2.0-2342485108 10.1016/j.nbd.2003.12.020 (Pubitemid 38569811)
37. Li X., Li H., Li X.-J., Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases. Brain Research Reviews 2008 59 1 245 252 2-s2.0-53749088439 10.1016/j.brainresrev.2008.08.003
38. Ciechanover A., Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel Lecture). Angewandte Chemie-International Edition 2005 44 37 5944 5967 2-s2.0-25144466132 10.1002/anie.200501428 (Pubitemid 41345912)
39. Chow W. N. V., Luk H. W., Chan H. Y. E., Lau K.-F., Degradation of mutant huntingtin via the ubiquitin/proteasome system is modulated by FE65. Biochemical Journal 2012 443 3 681 689 2-s2.0-84860115678 10.1042/BJ20112175
40. Li X., Wang -E C., Huang S., Xu X., Li -J X., Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments. Human Molecular Genetics 2010 19 2445 2455 10.1093/hmg/ddq127
41. Martín-Aparicio E., Yamamoto A., Hernández F., Hen R., Avila J., Lucas J. J., Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. Journal of Neuroscience 2001 21 22 8772 8781 2-s2.0-0035889973 (Pubitemid 33054841)
42. Menzies F. M., Hourez R., Imarisio S., Raspe M., Sadiq O., Chandraratna D., O'Kane C., Rock K. L., Reits E., Goldberg A. L., Rubinsztein D. C., Puromycin-sensitive aminopeptidase protects against aggregation-prone proteins via autophagy. Human Molecular Genetics 2010 19 23 4573 4586 2-s2.0-78149277418 10.1093/hmg/ddq385
43. Mizushima N., Yoshimori T., How to interpret LC3 immunoblotting. Autophagy 2007 3 6 542 545 2-s2.0-35848967804 (Pubitemid 350060049)
44. Ramassamy C., Longpré F., Christen Y., Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Current Alzheimer Research 2007 4 3 253 262 2-s2.0-34347370406 10.2174/156720507781077304 (Pubitemid 47025423)
45. Moosmann B., Behl C., Antioxidants as treatment for neurodegenerative disorders. Expert Opinion on Investigational Drugs 2002 11 10 1407 1435 2-s2.0-0036799799 10.1517/13543784.11.10.1407 (Pubitemid 35174938)
46. DeKosky S. T., Williamson J. D., Fitzpatrick A. L., Kronmal R. A., Ives D. G., Saxton J. A., Lopez O. L., Burke G., Carlson M. C., Fried L. P., Kuller L. H., Robbins J. A., Tracy R. P., Woolard N. F., Dunn L., Snitz B. E., Nahin R. L., Furberg C. D., Ginkgo biloba for prevention of dementia: a randomized controlled trial. The Journal of the American Medical Association 2008 300 19 2253 2262 2-s2.0-56649112752 10.1001/jama.2008.683
47. Liu X.-P., Goldring C. E. P., Wang H.-Y., Copple I. M., Kitteringham N. R., Park B. K., Extract of Ginkgo biloba induces glutathione-S-transferase subunit-P1 in vitro. Phytomedicine 2009 16 5 451 455 2-s2.0-64449088961 10.1016/j.phymed.2008.11.001
48. Dantuma N. P., Lindsten K., Glas R., Jellne M., Masucci M. G., Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome- dependent proteolysis in living cells. Nature Biotechnology 2000 18 5 538 543 2-s2.0-0034023407 10.1038/75406 (Pubitemid 30313959)
49. Sánchez I., Mahlke C., Yuan J., Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003 421 6921 373 379 2-s2.0-0037461730 10.1038/nature01301 (Pubitemid 36157935)
50. Koga H., Kaushik S., Cuervo A. M., Protein homeostasis and aging: the importance of exquisite quality control. Ageing Research Reviews 2011 10 2 205 215 2-s2.0-79251498807 10.1016/j.arr.2010.02.001
51. Goldberg Y. P., Kremer B., Andrew S. E., Theilmann J., Graham R. K., Squitieri F., Telenius H., Adam S., Sajoo A., Starr E., Heiberg A., Wolff G., Hayden M. R., Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects. Nature Genetics 1993 5 2 174 179 2-s2.0-0027359989 10.1038/ng1093-174 (Pubitemid 23293454)
52. Lakhani V. V., Ding F., Dokholyan N. V., Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences. PLoS Computational Biology 2010 6 4 2-s2.0-77954616668 10.1371/journal.pcbi.1000772
53. Wetzel R., Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. Journal of Molecular Biology 2012 421 4-5 466 490 2-s2.0-84863990252 10.1016/j.jmb.2012.01.030
54. Bence N. F., Sampat R. M., Kopito R. R., Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001 292 5521 1552 1555 2-s2.0-0035947372 10.1126/science.292.5521.1552 (Pubitemid 32493425)
55. Hipp M. S., Patel C. N., Bersuker K., Riley B. E., Kaiser S. E., Shaler T. A., Brandeis M., Kopito R. R., Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease. Journal of Cell Biology 2012 196 5 573 587 2-s2.0-84859983420 10.1083/jcb.201110093
56. Li J., Horak K. M., Su H., Sanbe A., Robbins J., Wang X., Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. Journal of Clinical Investigation 2011 121 9 3689 3700 2-s2.0-80052386730 10.1172/JCI45709
57. Verhoef LGGC, Lindsten K., Masucci M. G., Dantuma N. P., Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Human Molecular Genetics 2002 11 22 2689 2700 10.1093/hmg/11.22.2689
58. Lee C., Schwartz M. P., Prakash S., Iwakura M., Matouschek A., ATP-dependent proteases degrade their substrates by processively unraveling them from the degradation signal. Molecular Cell 2001 7 3 627 637 2-s2.0-0035266072 10.1016/S1097-2765(01)00209-X (Pubitemid 32706354)
59. Yang H., Liu J., Dou Q. P., Targeting tumor proteasome with traditional Chinese medicine. Current Drug Discovery Technologies 2010 7 1 46 53 2-s2.0-77951727526 10.2174/157016310791162785
60. Wang L. N., Wang Y., Lu Y., Yin Z. F., Zhang Y. H., Aslanidi G. V., Srivastava A., Ling C. G., Ling C., Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. Journal of Integrative Medicine 2014 12 1 20 34 10.1016/S2095-4964(14)60003-0